News | February 10, 2026
GSK India crosses Rs. 1,000 crore mark, key portfolios drive 8.1% topline growth
Launched in August 2025, GSK India’s Oncology business is rapidly gaining momentum
Launched in August 2025, GSK India’s Oncology business is rapidly gaining momentum
The company hopes to build on this momentum in the coming quarters and continue to focus on our key brands to drive sustainable profitable growth
The company is bringing precision therapies for gynaecological cancers
The performance was below anticipated levels, primarily due to external factors such as seasonal disruption that affected overall results
New Board of Directors and management team at Suven Pharma also appointed
He is a seasoned business leader with a successful track record of over 26 years across local and area roles within the pharmaceutical industry
Subscribe To Our Newsletter & Stay Updated
